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Abstract Clostridium botulinum type A hemagglutinin-positive
progenitor toxin consists of three distinct components: neuro-
toxin (NTX), hemagglutinin (HA), and non-toxic non-HA
(NTNH). The HA consists of four subcomponents designated
HA1, 2, 3a and 3b. By employing purified toxin and GST-fusion
proteins of each HA subcomponent, we found that the HA-
positive progenitor toxin, GST-HA1 and GST-HA3b bind to
human erythrocytes and microvilli of guinea pig upper small
intestinal sections. The HA-positive progenitor toxin and GST-
HA1 bind via galactose moieties, GST-HA3b binds via sialic
acid moieties. GST-HA2 and GST-HA3a showed no detectable
binding.
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1. Introduction
Clostridium botulinum neurotoxin (NTX, MrV150 000) has
seven serotypes, A^G, and exists as a stable complex due to
association with non-toxic proteins. The complex, designated
as the progenitor toxin, is found in three forms; 12S toxin, 16S
toxin and 19S toxin [1]. Type A progenitor toxin is composed
of these three forms. By comparative genetic and biochemical
analyses of the progenitor toxins, precise subunit structures
have been elucidated [2^6]. The 12S toxin consists of a NTX
and a non-toxic component having no hemagglutinin (HA)
activity and is designated as non-toxic non-HA (NTNH).
The 16S toxin consists of an NTX, NTNH and HA. Type A
HA consist of four di¡erent subcomponents: HA3b, HA1,
HA3a and HA2 that correspond to HA-52, HA-35,
HA-19V20 and HA-15 [7]. The 19S toxin is a dimer of 16S
toxin, and is presumed to be crosslinked through HA1 [7].
NTX is a highly potent inhibitor of the neurotransmitter
release from the peripheral nerve terminus. This poisoning
mechanism involves the cleavage of proteins associated with
the fundamental process of exocytosis [8,9]. Food-borne bot-
ulism is caused by ingestion of material containing the pro-
genitor toxin. Orally ingested progenitor toxin is absorbed
from the upper small intestine into the lymphatic system [1],
which then enters the blood stream, and reaches peripheral
nerves, where neurological dysfunction is elicited. The non-
toxic components play an important role in the food-borne
botulism. It has been reported that the progenitor toxins pos-
sess greater potential for oral toxicity than NTX alone, since
the former is more resistant to low pH and proteases in the
digestive tract [1]. Recently, HA has been found to function as
an adhesin allowing the type C 16S toxin to bind to the micro-
villi of the upper small intestine, which leads to the e⁄cient
absorption of the toxin [10].
In the toxin complex, HA-subcomponents are associated
non-covalently, and it is technically di⁄cult to isolate each
viable HA-subcomponent by protein chemical procedures.
Thus, the roles of each subcomponent in binding to intestinal
microvilli and erythrocytes have only been vaguely de¢ned. In
this study, we produced all four type A HA subcomponents as
recombinant proteins, and de¢nitively identi¢ed the HA sub-
components that possess the ability to bind to intestinal mi-
crovilli and erythrocytes.
2. Materials and methods
2.1. Puri¢cation of progenitor toxins and their antisera
The type A HA positive progenitor toxin (a mixture of 16S and 19S
toxins) and HA negative progenitor toxin (12S toxin) were puri¢ed
from the culture £uid of C. botulinum type A strain 62A as described
previously [11]. The antisera against each of these progenitor toxins
were those previously prepared [11,12].
2.2. Construction of expression vectors
Puri¢ed DNA from type A strain NIH was used as a template for
ampli¢cation by polymerase chain reaction as described previously
[13,14]. The following primers were designed from type A HA com-
ponent locus sequence [15]: Primer A1F, 5P-AACGGATCCCCG-
TAATCCAAAATTCATTAAAT-3P ; primer A1R, 5P-ATAGTCGA-
CTTATGGGTTACGAATATTCCA-3P ; primer A2F, 5P-TGAGG-
ATCCCCTCAGTTGAAAGAACTTTTCT-3P ; primer A2R, 5P-TTT-
GTCGACTTATATTTTTTCAAGTTTGAACA-3P ; primer A3F, 5P-
TTAGGATCCCCAGTGATACTATTGATTTAG-3P ; primer A3R,
5P-TGTGTCGACTTATTTAGAATTAAAAATATTGTTA-3P ; prim-
er A4F, 5P-TTAGGATCCCCGTTAGTAGCACACAACGAG-3P ;
primer A4R, 5P-CGTGTCGACTTAATTAGTAATATCTATATGC-
3P. Sequences encoding HA1, HA2, HA3a and HA3b were obtained
with the primer pairs A1F/A1R,A2F/A2R, A3F/A3R and A4F/A4R,
respectively. These primer combinations introduced a novel BamHI
site at the 5P end and a stop codon and SalI site at the 3P end. The
products were restricted with BamHI and SalI and, after puri¢cation
by agarose gel electrophoresis, were inserted in an expression vector
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pGEX-5X-3 (Amersham Pharmacia Biotech) restricted with the same
enzymes. The sequences of the constructs were veri¢ed by cycle se-
quencing on a 373A DNA sequencer (Perkin-Elmer).
2.3. Expression and puri¢cation of recombinant HA subcomponents
The GST-fusion proteins were expressed and a⁄nity puri¢ed using
Glutathione Sepharose 4B from lysates of recombinant Escherichia
coli (DH5a) as recommended by the supplier (Amersham Pharmacia
Biotech).
In order to isolate the HA polypeptides from the GST moiety, each
fusion protein was cleaved by addition of biotin-labelled factor Xa
(Restriction Protease Factor Xa Cleavage and Removal kit, Boehr-
inger) and incubation for 5 h at 25‡C (enzyme:substrate weight ratio
of 1:100). After removing the biotin-labelled factor Xa by using the
streptavidin gel (Restriction Protease Factor Xa Cleavage and Re-
moval kit), the pure HA subcomponent was obtained by using a
Glutathione Sepharose 4B column as described by the supplier (Amer-
sham Pharmacia Biotech).
2.4. SDS^PAGE and immunoblot analysis
SDS^PAGE was performed by the method of Laemmli [16] by
using a 4% stacking gel and a 8^16% gradient separating gel under
reducing conditions. For immunoblot analysis, proteins were electro-
transferred, reacted with 1:104-diluted rabbit anti-type A HA-positive
progenitor toxin serum, and then reactive bands were visualized using
the ECL detection system (Amersham Pharmacia Biotech) as de-
scribed previously [7].
2.5. Binding assay with intestinal tissue sections
Binding experiments of the progenitor toxins and recombinant pro-
teins to paraformaldehyde-¢xed sections of guinea pig upper small
intestine was performed as described previously [10]. As the ¢rst anti-
body, rabbit anti-type A HA-positive progenitor toxin serum (1:103
dilution), rabbit anti-type A HA-negative progenitor toxin serum
(1:103 dilution), and goat anti-GST antibody (1:3U103 dilution,
Amersham Pharmacia Biotech) were used for detection of type A
HA-positive progenitor toxin, HA-negative progenitor toxin and
GST-fusion proteins, respectively.
Sialidase treatment of the section was performed under the same
condition as described previously [10], using Arthrobacter ureafaciens
neuraminidase (highly puri¢ed preparation containing no protease, N-
acetylneuraminic acid (NeuAc) aldolase or glycosidase; Nacalai tes-
que). For saccharide inhibition experiments, type A HA-positive pro-
genitor toxin and fusion proteins were pre-incubated with saccharides
(¢nal concentration: 100 mM) for 1 h at 4‡C, and then the mixture
was reacted with sections.
2.6. Binding assay with erythrocytes
Binding of the progenitor toxins and recombinant proteins to er-
ythrocytes was determined in a microassay as previously described by
Hoschu«tzky et al. [17] with minor modi¢cation. Microtiter plates
(EIA/RIA Plate, Costar) were coated with the toxins or recombinant
proteins (100 mg/ml, 50 ml per well) at 4‡C for 16 h. The wells were
C
Fig. 1. A: Genetic organization of type A progenitor toxin genes.
Data summarized from Henderson et al. [15] and Fujita et al. [13].
Hatched boxes represent the genes for HA subcomponents. Letters
above boxes refer to the designation of type A progenitor toxin
genes. The arrows refer to the direction of transcription of the
genes. The ha3 gene product is a precursor of the HA3a and HA3b
[2]. The N-terminal amino acid of HA3a20 is 20Ser. B: GST-HA
subcomponent fusion proteins. Factor Xa cleavage sites and HA
protein start sites are denoted by arrows. * Molecular masses were
calculated from amino acid sequences of fusion proteins. C: Electro-
phoretic analysis of GST-free HA proteins and HA subcomponents
from type A HA-positive progenitor toxin. Proteins were visualized
by staining with Coomassie Blue R-250 (Merck). Lane M, molecular
weight standards (Broad Range, Bio-Rad); lane 1, GST-free HA2;
lane 2, GST-free HA3a20 ; lane 3, GST-free HA1; lane 4, GST-free
HA3b; lane 5, type A HA-positive progenitor toxin. Subcompo-
nents of type A HA-positive progenitor toxin were indicated on the
right side. D: Western blotting of panel C with a rabbit anti-type A
HA-positive progenitor toxin serum.
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washed twice with PBS, and free binding sites were blocked with 1%
bovine serum albumin (BSA) in PBS at room temperature for 2 h.
Then the wells were incubated with a 1% suspension of human type O
erythrocytes in PBS containing 1% BSA at room temperature for
30 min. The wells were carefully washed ¢ve times with PBS, the
adherent erythrocytes were lysed with H2O (50 Wl per well), and an
absorbance at 405 nm of the hemoglobin was taken as a measure of
the number of adherent erythrocytes. The binding inhibition test with
a di¡erent amount of saccharides was also performed as described
above.
2.7. Sialidase treatment of erythrocytes
Human type O erythrocytes (10% suspension in PBS) were treated
with A. ureafaciens neuraminidase (Nacalai tesque) at a ¢nal concen-
tration of 0.01 U/ml, at 37‡C for 1 h. Thereafter, the erythrocytes
were washed twice with PBS and suspended in PBS (50% suspension).
3. Results and discussion
3.1. Expression and puri¢cation of recombinant
HA subcomponents
All four type A HA-subcomponents were produced as re-
combinant proteins fused to the GST (Fig. 1A,B). Each HA
subcomponent polypeptide was designed to extend from the
same N-terminal amino acid residue as the corresponding HA
subcomponent of type A HA-positive progenitor toxin [7].
After elimination of the GST moiety by using factor Xa pro-
tease, the GST-free HA proteins were analyzed by SDS^
PAGE (Fig. 1C). The apparent relative molecular masses of
all the GST-free HA proteins except GST-free HA3a20 were
similar to those of the HA subcomponents from HA-positive
progenitor toxin (native HA subcomponents). The GST-free
HA3a20 was approximately Mr 4000 (about 36 amino acid
residues) larger than the native HA3a20. As the GST-free
HA-subcomponents had only three extra amino acids (Gly-
Ile-Pro) derived from the vector, it is possible that the native
HA3a20 undergoes C-terminal processing by endogenous pro-
teases. The C-terminal amino acid sequence of the native
HA3a20 will be determined to con¢rm this speculation.
The antigenic integrity of GST-free HA proteins was con-
¢rmed by Western blotting (Fig. 1D). All the recombinant
proteins except GST-free HA2 were immuno-reactive with
anti-type A HA-positive progenitor toxin serum, which was
similar to results observed using the HA subcomponents
from 16S and 19S toxins. The immuno-reactivity of native
Fig. 2. Light micrograph of upper small intestine of guinea pig incu-
bated with type A HA-positive progenitor toxin (1 Wg/ml) (A),
GST-HA3b (50 Wg/ ml) (B), GST-HA1 (50 Wg/ ml) (C), and GST
alone (50 Wg/ ml) (D). Adherent molecules were stained brown. As
the ¢rst antibodies, rabbit anti-type A HA-positive progenitor toxin
serum (A), and goat anti-GST antibody (B) (C) (D) were used. Sec-
tions were counterstained blue with hematoxylin. The same results
were obtained in three repeats of this experiment, and each was
done in duplicate. Arrows point to the location of stained blood
capillary endothelia. Bars, 50 Wm.
Table 1
Binding pro¢les of type A progenitor toxins and GST-HA proteins to the intestinal microvilli and erythrocytes
HA-positive progenitor toxin GST-HA3b GST-HA1
Binding to intestinal microvilli
no treatment ++ ++ +
Neuroaminidase-treatment ++ 3 ++
In the presence of sugar (100 mM)
Lac 0 NT 0
Gal 0 NT 0
Glc ++ NT +
Binding to erythrocytes
no treatment ++ ++ ++
Neuroaminidase-treatment ++ 3 ++
In the presence of sugar (100 mM)
Lac + ++ 3
Gal + ++ 3
Glc ++ ++ ++
Assays were performed in three independent experiments, and gave essentially the same results. Intensity of binding: 3, absent; 0, trace; +,
weak; ++, intense. For an example of ++, see Fig. 2a,b. NT, not tested.
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HA2 was very weak compared with other components as
described previously [7]; likewise, GST-free HA2 was also
very weak.
3.2. HA component of type A HA-positive progenitor toxin
binds to the intestinal microvilli
Binding experiments were performed using intestinal tissue
sections. Type A HA-positive progenitor toxin (a mixture of
16S and 19S toxins) showed intense binding to the microvilli
(Fig. 2 and Table 1), whereas HA-negative progenitor toxin
(12S toxin) did not show any binding, as reported for type C
progenitor toxins [10]. Given that type C 16S toxin exhibits
NeuAc-dependent binding activity [10], the ability of type A
HA-positive progenitor toxin to adhere to sialidase-treated
intestinal sections was tested. The sialidase treatment showed
no change in type A HA-positive progenitor toxin binding
(Fig. 2 and Table 1). In order to examine ligand(s) for type
A HA-positive progenitor toxin on microvilli, binding inhibi-
tion experiments using three di¡erent saccharides were carried
out (Table 1). Binding was drastically inhibited by 100 mM
lactose (Lac) and 100 mM galactose (Gal), but not by 100
mM glucose (Glc). These results indicate that the HA but not
NTNH or NTX, components of type A HA-positive progen-
itor toxin exhibit binding activity on microvilli, as observed
for type C. However, unlike type C HA, the Gal moieties on
the microvilli glycoconjugates mediate toxin binding.
3.3. HA1 and HA3b exhibit binding activity toward intestinal
microvilli and erythrocytes
The binding of the GST-HA subcomponents to intestinal
tissue sections was analyzed. Given that the immuno-reactiv-
ity of HA2 was very weak, we utilized the GST-HA fusion
proteins and anti-GST antibody to detect these binding activ-
ities. As shown in Fig. 2 and Table 1, GST-HA1 and GST-
HA3b showed binding to microvilli, whereas GST alone,
GST-HA2 and GST-HA3a20 did not. In contrast to GST-
HA1, GST-HA3b and HA-positive progenitor toxin also
bound to blood capillary endothelia. Sialidase treatment of
the sections completely abolished GST-HA3b binding to mi-
crovilli, but slightly increased GST-HA1 binding. The binding
of GST-HA1 to microvilli was obviously inhibited by 100 mM
Lac and 100 mM Gal, but not by 100 mM Glc (Table 1).
The binding activity of the GST-HA subcomponents to
erythrocytes was also analyzed. Immobilized GST-HA pro-
teins and progenitor toxins were used in a microassay and
as shown in Fig. 3 and Table 1, GST-HA1 and GST-HA3b
showed the same binding activities as type A HA-positive
progenitor toxin. Type A HA-negative progenitor toxin,
GST-HA2, GST- HA3a20 and GST alone showed no binding
activity. Sialidase treatment of erythrocytes completely abol-
ished the adhesion activity of GST-HA3b, but did not a¡ect
GST-HA1 and type A HA-positive progenitor toxin binding.
The binding of GST-HA1 was drastically inhibited by 100
mM of Lac, and Gal, but not by 100 mM Glc. These inhib-
itions were dose-dependent and the half-maximal inhibition
occurred at about 50 mM for Lac and 20 mM for Gal (Fig.
4C). The binding of type A HA-positive progenitor toxin to
the erythrocytes was partially inhibited by 100 mM of Lac
and Gal, but was not inhibited by 100 mM of Glc (Table 1,
Fig. 4A,B). It is likely that the type A HA-positive progenitor
toxin recognized the other ligand(s) in addition to Gal-based
carbohydrates on erythrocyte cells. Another possibility is that
type A HA-positive progenitor toxin binds with high a⁄nity
to the Gal-based carbohydrates on erythrocyte membrane and
Fig. 3. Binding properties of progenitor toxins and GST-HA pro-
teins to erythrocytes. Background binding to BSA was minimal and
was subtracted from the absorbance values. Each point is the
mean þ S.D. of triplicate wells. The experiment depicted is represen-
tative of the three experiments performed. A405, Absorbance at
405 nm.
Fig. 4. E¡ect of saccharides on the heme-adhesion of HA-positive
progenitor toxin and GST-HA1 and HA-3b. HA-positive progenitor
toxin coated wells (A,B) were incubated for 1 h at 4‡C with various
saccharides (100 mM) prior to addition of untreated erythrocytes
(A) or neuraminidase treated erythrocytes (B), and bound erythro-
cytes were determined. Background binding to BSA was minimal
and was subtracted from the absorbance values. Each point is the
mean þ S.D. of triplicate wells. E¡ect of di¡erent amount of saccha-
rides (E, Gal; 8, Lac; a, Glc) on the binding of GST-HA1 (C)
and GST-HA3b (D) to untreated erythrocytes was also observed in
the same manner.
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is therefore not inhibited e⁄ciently by Gal-based mono- or di-
saccharides. In case of GST-HA3b, little decrease of binding
to erythrocytes was observed even though 200 mM of these
three saccharides were added (Fig. 4D).
From the results of binding assays using intestinal tissue
sections and erythrocytes, HA1 and HA3b were identi¢ed as
the adhesive subcomponents to microvilli and erythrocytes,
and Gal moieties on carbohydrates side chains on microvilli
and erythrocyte are important for the binding of HA1, where-
as NeuAc moieties are important for the binding of HA3b.
The observation that the type A HA has two di¡erent ad-
hesive subcomponents, HA1 and HA3b, raises the question of
whether one or both of these subcomponents in the type A
HA-positive progenitor toxin contribute to the binding activ-
ity of the HA-positive progenitor toxin. Our results suggest
the binding of type A HA-positive progenitor toxin to siali-
dase-treated cells may be attributed to the HA1 molecule, as
recombinant HA3b showed no binding activity on these cells.
At present, there is no direct evidence indicating the contri-
bution of the HA3b to the HA-positive progenitor toxin bind-
ing activity, however, recombinant HA3b showed more in-
tense binding to the microvilli than recombinant HA1. In
addition, the binding of type A HA-positive progenitor toxin
to blood capillary endothelia on intestinal tissue sections may
be attributed to the HA3b molecule, as recombinant HA1 did
not bind these cells. The elucidation of the precise roles of
these two subcomponents in binding and absorption of type A
HA-positive progenitor toxin in the small intestine requires
more detailed analysis with type A HA-positive progenitor
toxin, HA1, and HA3b.
We previously reported that only HA1, out of four HA
subcomponents, exists alone as a multimer in the culture
supernatant of C. botulinum types A and D. These HA1 multi-
mers, however, have little HA activity [7,18]. Fu et al. per-
formed similar experiments but found that the unassembled
type A HA1 possesses HA activity [19]. We are now preparing
each HA subcomponent of types A^D as recombinant pro-
teins in an attempt to clarify their binding and HA activities.
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